Invesco Ltd. cut its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 84.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,992 shares of the company's stock after selling 438,018 shares during the quarter. Invesco Ltd. owned 0.15% of Kodiak Sciences worth $227,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of KOD. US Bancorp DE lifted its stake in Kodiak Sciences by 131.7% during the first quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after buying an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Kodiak Sciences in the first quarter worth approximately $28,000. Aries Wealth Management purchased a new stake in shares of Kodiak Sciences in the first quarter worth approximately $70,000. XTX Topco Ltd purchased a new stake in shares of Kodiak Sciences in the first quarter worth approximately $126,000. Finally, Public Employees Retirement System of Ohio lifted its position in shares of Kodiak Sciences by 183.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company's stock worth $147,000 after purchasing an additional 9,560 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.
Kodiak Sciences Price Performance
NASDAQ:KOD traded down $0.67 during mid-day trading on Friday, reaching $9.25. The stock had a trading volume of 373,109 shares, compared to its average volume of 609,787. The business's 50 day moving average is $7.88 and its 200 day moving average is $5.02. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60. The stock has a market cap of $488.59 million, a P/E ratio of -2.43 and a beta of 2.45.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02). Equities analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Barclays increased their price target on shares of Kodiak Sciences from $4.00 to $7.00 and gave the stock an "underweight" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. raised shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target for the company in a research report on Thursday, August 14th. Finally, HC Wainwright increased their price objective on Kodiak Sciences from $3.00 to $5.00 and gave the stock a "neutral" rating in a report on Monday, August 18th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $11.75.
Check Out Our Latest Stock Analysis on Kodiak Sciences
Kodiak Sciences Profile
(
Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Further Reading
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
